AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12602644 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC)
Number of subjects: 0
Study 12602644 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring substance abuse, treatment nonadherence, and outpatient services intensity
Number of subjects: 0
Study 11014510 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based DHE lesson plus two small-group sessions
Number of subjects: 449
Study 11014510 — intervention group
Group type: COMPARATOR
Intervention: Single classroom-based DHE lesson
Number of subjects: 449
Study 9360781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine stopped on day 60
Number of subjects: 103
Study 9360781 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine continued for 180 days
Number of subjects: 103
Study 7903326 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone 5 mg t.i.d.
Number of subjects: 249
Study 7903326 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone 10 mg t.i.d.
Number of subjects: 249
Study 7903326 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 5 mg t.i.d.
Number of subjects: 249
Study 7903326 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 249
Study 3936946 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (Mitomycin‐C + FT 207 + OK 432 + PSK)
Number of subjects: 58
Study 3936946 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Mitomycin‐C + FT 207)
Number of subjects: 58
Study 31566399 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-based intervention
Number of subjects: 150
Study 31566399 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 150
Study 30281320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3001
Study 30281320 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 3001
Study 29789969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus Letrozole
Number of subjects: 195
Study 29789969 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 195
Study 26701357 — intervention group
Group type: EXPERIMENTAL
Intervention: BD FlowSmart infusion set
Number of subjects: 85
Study 25037617 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical Performance Score (TPS) - Class 1 (optimal), Class 2 (adequate), Class 3 (inadequate)
Number of subjects: 549
Study 22349482 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg ingested on 2 separate days)
Number of subjects: 16
Study 22349482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21028997 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 21028997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 17342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 2588
Study 17342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric PPI treatment
Number of subjects: 2588
Study 17342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 2588
Study 15187379 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-prandial supine posture
Number of subjects: 0
Study 15187379 — intervention group
Group type: COMPARATOR
Intervention: Post-prandial sitting posture
Number of subjects: 0
Study 11681223 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis
Number of subjects: 100
Study 11681223 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 100
Study 9575461 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letter from the general practitioner recommending mammography
Number of subjects: 473
Study 9575461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no letter)
Number of subjects: 473
Study 8195335 — intervention group
Group type: EXPERIMENTAL
Intervention: Human biosynthetic growth hormone (HGH; 12 IU/day)
Number of subjects: 40
Study 8195335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2958398 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 10 mg sublingually
Number of subjects: 20
Study 2958398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 20
Study 2958398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually followed by Isosorbide dinitrate (ISDN) 10 mg
Number of subjects: 20
Study 2958398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 20
Study 29022736 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills & Resiliency Track (n = 97)
Number of subjects: 200
Study 29022736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Track (n = 38)
Number of subjects: 200
Study 29022736 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Track (n = 34)
Number of subjects: 200
Study 27608604 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation of left dlPFC
Number of subjects: 0
Study 27608604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation of left dlPFC
Number of subjects: 0
Study 27608604 — intervention group
Group type: COMPARATOR
Intervention: Right dlPFC stimulation (both anodal and cathodal)
Number of subjects: 0
Study 27608604 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline impulsivity analysis
Number of subjects: 0
Study 24690370 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 36
Study 24690370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22200382 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based conservative care (protocol of care)
Number of subjects: 118
Study 22200382 — intervention group
Group type: COMPARATOR
Intervention: Usual conservative care
Number of subjects: 118
Study 21047590 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (PSA testing every 4 years)
Number of subjects: 182160
Study 21047590 — intervention group
Group type: COMPARATOR
Intervention: Control arm (usual care)
Number of subjects: 182160
Study 18321010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with high intimacy relationship history
Number of subjects: 414
Study 18321010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with medium intimacy relationship history
Number of subjects: 414
Study 18321010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with low intimacy relationship history
Number of subjects: 414
Study 18321010 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 414
Study 18321010 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 414
Study 15653117 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang 1200 mg/day
Number of subjects: 48
Study 15653117 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang 2400 mg/day
Number of subjects: 48
Study 12121726 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 103
Study 12121726 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 103
Study 10554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of ICA antibodies
Number of subjects: 156
Study 10554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of anti-GAD antibodies
Number of subjects: 156
Study 10554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of IA-2 antibodies
Number of subjects: 156
Study 10554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 2 types of antibodies
Number of subjects: 156
Study 10554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight of children
Number of subjects: 156
Study 10554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous pregnancies
Number of subjects: 156
Study 8904364 — intervention group
Group type: EXPERIMENTAL
Intervention: Laptop computers with 9 hours of computer instruction
Number of subjects: 38
Study 8904364 — intervention group
Group type: COMPARATOR
Intervention: Usual manner of completing assignments (comparison group)
Number of subjects: 38
Study 2000923 — intervention group
Group type: EXPERIMENTAL
Intervention: Futuro prefabricated wrist brace (No. 33)
Number of subjects: 20
Study 2000923 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar thumbhole orthosis
Number of subjects: 20
Study 2000923 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar orthosis with radial connector bar
Number of subjects: 20
Study 2000923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal orthosis with distal transverse arch support
Number of subjects: 20
Study 2000923 — intervention group
Group type: COMPARATOR
Intervention: All orthoses
Number of subjects: 20
Study 6640248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 0
Study 6640248 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 0
Study 6640248 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 30712687 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time wear of Twin-block appliance (12 hours daily)
Number of subjects: 62
Study 30712687 — intervention group
Group type: COMPARATOR
Intervention: Full-time wear of Twin-block appliance (22 hours daily)
Number of subjects: 62
Study 28323044 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium doses of vitamin D (1600, 2400, 3200 IU)
Number of subjects: 7
Study 28323044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of vitamin D (400, 800 IU)
Number of subjects: 7
Study 28323044 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamin D (4000, 4800 IU)
Number of subjects: 7
Study 28323044 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25OHD quintiles
Number of subjects: 7
Study 28323044 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup with a fall history
Number of subjects: 7
Study 27267679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 120
Study 27267679 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 120
Study 24820858 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ginger, two times per day, 30 min before each dose of antiretroviral regimen for 14 days
Number of subjects: 102
Study 24820858 — intervention group
Group type: COMPARATOR
Intervention: Placebo, two times per day, 30 min before each dose of antiretroviral regimen for 14 days
Number of subjects: 102
Study 22721261 — intervention group
Group type: COMPARATOR
Intervention: Curtin University's Activity, Food and Attitudes Program (CAFAP), an 8-week intensive multidisciplinary program with follow-up assessments at 3, 6, and 12 months.
Number of subjects: 96
Study 19878784 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU) imaging
Number of subjects: 496
Study 19878784 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT) imaging
Number of subjects: 496
Study 19878784 — intervention group
Group type: COMPARATOR
Intervention: CDU imaging vs CT imaging
Number of subjects: 496
Study 18158045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 60
Study 18158045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic contractions evoked by 10-Hz ulnar nerve stimulation
Number of subjects: 30
Study 15079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitch contractions evoked by single ulnar nerve stimulation
Number of subjects: 30
Study 15079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic RT (90 to 5%)
Number of subjects: 30
Study 15079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitch RT (90 to 5%)
Number of subjects: 30
Study 15079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of RT with leukocyte CTG repeat length
Number of subjects: 30
Study 15079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest variability for tetanic RT
Number of subjects: 30
Study 15079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest variability for tetanic PF
Number of subjects: 30
Study 10580169 — intervention group
Group type: EXPERIMENTAL
Intervention: N-monomethyl-L-arginine (LNMMA)
Number of subjects: 8
Study 10580169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9357351 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone help line plus active telephone outreach
Number of subjects: 509
Study 9357351 — intervention group
Group type: COMPARATOR
Intervention: Group session without telephone support
Number of subjects: 509
Study 9357351 — intervention group
Group type: COMPARATOR
Intervention: Session plus access to a toll‐free help line
Number of subjects: 509
Study 8174950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg twice daily)
Number of subjects: 66
Study 8174950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8174950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 66
Study 3515333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naproxen (250 mg per day for two weeks)
Number of subjects: 21
Study 3515333 — intervention group
Group type: COMPARATOR
Intervention: Local injection of betamethasone (6 mg in a long-acting form)
Number of subjects: 21
Study 2893916 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg twice daily
Number of subjects: 433
Study 2893916 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin 0.125 mg twice daily
Number of subjects: 433
Study 2893916 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 433
Study 2893916 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 433
Study 30737610 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Medical Male Circumcision (VMMC) services in 2014/15
Number of subjects: 0
Study 30737610 — intervention group
Group type: COMPARATOR
Intervention: Voluntary Medical Male Circumcision (VMMC) services in 2013
Number of subjects: 0
Study 30737610 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of circumcision benefits
Number of subjects: 0
Study 30737610 — intervention group
Group type: COMPARATOR
Intervention: Perceived service availability in 2013
Number of subjects: 0
Study 30737610 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived service availability in 2014/15
Number of subjects: 0
Study 30737610 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of knowledge of prevention tools
Number of subjects: 0
Study 27871030 — intervention group
Group type: EXPERIMENTAL
Intervention: Body psychotherapy
Number of subjects: 275
Study 27871030 — intervention group
Group type: COMPARATOR
Intervention: Pilates
Number of subjects: 275
Study 26372401 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) administered after each of 10 CBT sessions
Number of subjects: 27
Study 26372401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) administered after each of 10 CBT sessions
Number of subjects: 27
Study 26372401 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) with high homework compliance
Number of subjects: 27
Study 23953385 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7243
Study 23953385 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7243
Study 21397483 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 μg, twice daily for 14 days)
Number of subjects: 24
Study 21397483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg, once daily for 14 days)
Number of subjects: 24
Study 21397483 — intervention group
Group type: COMPARATOR
Intervention: Single dose of Formoterol (200 μg)
Number of subjects: 24
Study 21397483 — intervention group
Group type: COMPARATOR
Intervention: Single dose of Tiotropium
Number of subjects: 24
Study 21397483 — intervention group
Group type: COMPARATOR
Intervention: Single dose of Salbutamol (200 μg)
Number of subjects: 24
Study 21397483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18344753 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 115
Study 18344753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 115
Study 18344753 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 115
Study 18344753 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%
Number of subjects: 115
Study 18344753 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 2%
Number of subjects: 115
Study 18344753 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone 0.15%
Number of subjects: 115
Study 18344753 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 115
Study 16586424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-contrast (DC) cluster analysis
Number of subjects: 21
Study 16586424 — intervention group
Group type: EXPERIMENTAL
Intervention: Scout geometry (SG) algorithm
Number of subjects: 21
Study 14531243 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based store-and-forward video home telehealth system
Number of subjects: 10
Study 14531243 — intervention group
Group type: COMPARATOR
Intervention: In-person asthma education
Number of subjects: 10
Study 14531243 — intervention group
Group type: COMPARATOR
Intervention: Interactive Web site asthma education
Number of subjects: 10
Study 10700672 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD Turbuhaler 600 microg qid
Number of subjects: 185
Study 10700672 — intervention group
Group type: COMPARATOR
Intervention: PRED 40 mg in the morning
Number of subjects: 185
Study 9596864 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐methyl‐PGF2 alpha 0.100 mg
Number of subjects: 150
Study 9596864 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐methyl‐PGF2 alpha 0.125 mg
Number of subjects: 150
Study 9596864 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐methyl‐PGF2 alpha 0.200 mg
Number of subjects: 150
Study 8404386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transproctoscopic Doppler ultrasound followed by local injection treatment with 5 percent phenol almond oil
Number of subjects: 80
Study 8404386 — intervention group
Group type: COMPARATOR
Intervention: Conventional sclerotherapy without Doppler investigation
Number of subjects: 80
Study 2948853 — intervention group
Group type: EXPERIMENTAL
Intervention: RA27/3 rubella vaccine from Institut Merieux
Number of subjects: 231
Study 2948853 — intervention group
Group type: COMPARATOR
Intervention: RA27/3 rubella vaccine from Wellcome
Number of subjects: 231
Study 31881096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 39
Study 31881096 — intervention group
Group type: EXPERIMENTAL
Intervention: Detached Mindfulness (DM)
Number of subjects: 39
Study 28866765 — intervention group
Group type: EXPERIMENTAL
Intervention: eReCog program (4-week duration, comprised of four online modules)
Number of subjects: 60
Study 28545277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic post-conditioning (IPC)
Number of subjects: 251
Study 26242331 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 10,000 i.u. for 7 consecutive days
Number of subjects: 42
Study 26242331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Epo treatment)
Number of subjects: 42
Study 26242331 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 42
Study 23870654 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised balance exercises (six 1-hour circuit classes)
Number of subjects: 162
Study 23870654 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (standard rehabilitation intervention including physiotherapy mobility training and exercise for at least two hours on each weekday)
Number of subjects: 162
Study 23870654 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised balance exercises
Number of subjects: 162
Study 21355659 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed scale measuring identity fusion
Number of subjects: 10
Study 21355659 — intervention group
Group type: COMPARATOR
Intervention: Earlier pictorial measure of identity fusion
Number of subjects: 10
Study 21355659 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal fusion scale (Spanish and English versions)
Number of subjects: 10
Study 18493215 — intervention group
Group type: EXPERIMENTAL
Intervention: whey-based formula with galacto- and long-chain fructo-oligosaccharides (scGOS/lcFOS group)
Number of subjects: 82
Study 18493215 — intervention group
Group type: EXPERIMENTAL
Intervention: whey-based formula with galacto- and long-chain fructo-oligosaccharides added with pectin-derived acidic oligosaccharides (scGOS/lcFOS/pAOS group)
Number of subjects: 82
Study 18493215 — intervention group
Group type: COMPARATOR
Intervention: whey-based formula (control group)
Number of subjects: 82
Study 16841269 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic rectopexy (surgical procedure)
Number of subjects: 0
Study 16841269 — intervention group
Group type: COMPARATOR
Intervention: Historic control study
Number of subjects: 0
Study 14631699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook Osteo-site needle
Number of subjects: 16
Study 14631699 — intervention group
Group type: COMPARATOR
Intervention: Cook Paediatric Intraosseus Insertion needle
Number of subjects: 16
Study 10772190 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-bore nasogastric tube (NGT)
Number of subjects: 30
Study 10772190 — intervention group
Group type: COMPARATOR
Intervention: No small-bore nasogastric tube (NGT)
Number of subjects: 30
Study 9353404 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (120 microg)
Number of subjects: 7
Study 9353404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8412310 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion carboplatin 250 mg/m2 per day for 5 days and etoposide 150 mg/m2 per day for 5 days.
Number of subjects: 32
Study 8412310 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion carboplatin 310 mg/m2 per day for 5 days and etoposide 150 mg/m2 per day for 5 days.
Number of subjects: 32
Study 8412310 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 32